# Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients

> **NCT07231809** · NA · NOT_YET_RECRUITING · sponsor: **AC.TA. S.r.l.** · enrollment: 50 (estimated)

## Conditions studied

- Non Muscle Invasive Bladder Cancer
- Bladder Cancer
- Carcinoma in Situ of Bladder
- Urinary Bladder Neoplasms
- Carcinoma, Transitional Cell, Bladder

## Interventions

- **PROCEDURE:** Hyperthermic Intravesical Chemotherapy (HIVEC)

## Key facts

- **NCT ID:** NCT07231809
- **Lead sponsor:** AC.TA. S.r.l.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-15
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07231809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07231809, "Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07231809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*